Patients who adhere to a CancerIQ cancer prevention plan, or cancer survivorship plan, are more likely to catch a cancer before it grows beyond 1 centimeter, says Feyi Olopade Ayodele, MBA, chief executive officer at CancerIQ.
Patients who adhere to a CancerIQ cancer prevention plan, or cancer survivorship plan, are more likely to catch a cancer before it grows beyond 1 centimeter, says Feyi Olopade Ayodele, MBA, chief executive officer at CancerIQ.
Transcript
What are the success rates for predicting cancer risk by using genetic services?
At CancerIQ, we look at success in multiple different ways. We are not a diagnostic test ourselves. We really do rely on some of the highest quality genetic testing labs that are out there and we partner with them to make sure our providers can access best-in-class genetic testing. But when it comes to the benefits or repeatable outcomes that CancerIQ can drive, this really is our secret sauce. We’ve already found that patients that adhere to a CancerIQ cancer prevention plan, or cancer survivorship plan are more likely to catch a cancer before it grows beyond 1 centimeter.
To date, in the case study that we’re going to talk about [at the Association of Community Cancer Centers 45th Annual Meeting & Cancer Center Business Summit], you’ll see that we were able to find 3 patients who already had cancer using that breast MRI that CancerIQ recommended before it grew beyond a centimeter. They had a much higher chance of survival, less costly treatment, and we’ve demonstrated, full circle, CancerIQ’s impact on early detection.
IQVIA Report Spotlights Shortages for Pain, Obesity, and Oncology Therapies
November 21st 2023A new report from IQVIA provides an overview of current US drug shortages, shedding light on major areas of concern, such as medications to address pain, cardiovascular conditions, obesity and diabetes, and multiple forms of cancer.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
Recent T1D Research Contradicts Common Assumptions About Patients
November 15th 2023Michael Fang, PhD, researcher and assistant professor in the division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University, discussed recent findings in the type 1 diabetes (T1D) space that may alter the way providers address diabetes diagnoses.
Read More